Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.
Yuanwang PanYuan HaoHan HanTing ChenHailin DingKristen E LabbeElaine ShumKayla GuidryHai HuFiona ShermanKe GengJanaye StephensAlison ChafitzSittinon TangHsin-Yi HuangChengwei PengChristina AlmonteJared E LopesHeather C LoseyRaymond J WinquistVamsidhar VelchetiHua ZhangKwok-Kin WongPublished in: Journal for immunotherapy of cancer (2022)
mNemvaleukin, a novel cytokine-based immunotherapy, significantly inhibited murine SCLC tumor growth and prolonged survival, which was further enhanced by the addition of chemotherapy. mNemvaleukin alone, and in combination with chemotherapy, drove a strong antitumor immune program elicited by cytotoxic immune cells. Our findings support the evaluation of nemvaleukin alone or in combination with chemotherapy in clinical trials for the treatment of SCLC.